Light-Scattering Technique May Pinpoint Protein Changes, Early Cataract Risk

Posted: January 13, 2009

Comments

Ocular Surgery News

A noninvasive imaging technique detected early protein changes associated with lens opacity and potential cataract in a National Eye Institute-NASA clinical trial.

Full Story

Cataract Products and Equipment »

All of the following drugs are FDA approved for the treatment of minimally classic subfoveal CNV in patients with neovascular AMD with evidence of recent disease progression (loss of vision, growth of CNV on FA, new macular hemorrhage) except for which one?
1. Pegaptanib sodium (Macugen)
2. Verteporfin (Visudyne PDT)
3. Ranibizumab (Lucentis)
4. None of the above
5. All of the above
Check The Answer

Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product
OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Light-Scattering Technique May Pinpoint Protein Changes, Early Cataract Risk

Comments

Related Categories

Cataract Products and Equipment »

Quick Quiz

All of the following drugs are FDA approved for the treatment of minimally classic subfoveal CNV in patients with neovascular AMD with evidence of recent disease progression (loss of vision, growth of CNV on FA, new macular hemorrhage) except for which one?

AdGlare RMR Ad

Cataract Featured Products

Smartphone-Based Retinal Screening System

OPMI LUMERA 700 Surgical Microscope

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us